Smart Eye Informs About the Outcome of the 2023 Share Rights Program
Rhea-AI Summary
Smart Eye (OTC:SMTEF) announced completion of its long-term 2023 Share Rights Program. After performance targets were met, 426,585 shares were allotted to participants and 93,700 shares were sold to cover social security costs. In total, 520,285 new shares from warrants series 2026:1 were issued, corresponding to about 1.3% dilution. The program, adopted on May 2, 2023, aims to attract and retain key employees.
Positive
- Performance target met, triggering allotment of 426,585 shares to participants
- Total 520,285 new shares issued through exercise of warrants series 2026:1
- Program designed to attract and retain key employees in the Group
- Share rights delivered to participants at no cost under program terms
Negative
- New shares correspond to approximately 1.3% dilution of total share count
- 93,700 shares sold to cover social security costs related to allotment
AI-generated analysis. How Rhea-AI works. Not financial advice.
GÖTEBORG, SE / ACCESS Newswire / May 25, 2026 / Smart Eye (STO:SEYE)(OTC PINK:SMTEF)(FRA:SE9)
Smart Eye AB (publ) today announces that the company's long-term incentive program, the 2023 Share Rights Program, has been completed in accordance with its established terms.
A total of 426,585 shares have been allotted to participants in the program after the performance target was met. To cover social security costs related to the allotment, an additional 93,700 shares have been sold via a financial intermediary. In total, 520,285 shares have been added through the exercise of warrants from series 2026:1.
The shares are delivered to participants at no cost, in accordance with the terms of the program.
The program was adopted by the annual general meeting on May 2, 2023, and was designed to strengthen Smart Eye's ability to attract and retain key employees within the Group.
The new shares correspond to a dilution of approximately
For more information:
Martin Krantz, CEO Smart Eye AB
+46 70-329 26 98
martin.krantz@smarteye.se
About Smart Eye
Smart Eye is the leading provider of Human Insight AI, technology that understands, supports and predicts human behavior in complex environments. The company is on a mission to bridge the gap between humans and machines for a safe and sustainable future. Supported by Affectiva and iMotions - companies it acquired in 2021 - Smart Eye's multimodal software and hardware solutions provide unparalleled insight into human behavior.
In automotive, Smart Eye's driver monitoring systems and interior sensing solutions improve road safety and the mobility experience. The company's eye tracking technology and iMotions biosensor software platform are also used in behavioral research to enable advanced research in academic and commercial sectors. In media analytics, Affectiva's Emotion AI provides the world's largest brands and market researchers with a deeper understanding of how consumers engage with content, products, and services.
Founded in 1999, Smart Eye is a global company headquartered in Sweden, with customers including NASA, Nissan, Boeing, Honeywell, Volvo, GM, BMW, Polestar, Geely, Harvard University, 28 percent of the Fortune Global 500 companies, and over 1,300 research organizations around the world.
Visit www.smarteye.ai for more information.
Visit our investor web for more financial information: https://smarteye.se/investors/
Smart Eye is listed on the Nasdaq First North Growth Market. The Company's Certified Adviser is Bergs Securities AB.
SOURCE: Smart Eye
View the original press release on ACCESS Newswire